Famotidine adjunctive pharmacotherapy of schizophrenia : a case report
Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to t...
Gespeichert in:
| Veröffentlicht in: | Clinical neuropharmacology 1995-08, Vol.18 (4), p.369-374 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 374 |
|---|---|
| container_issue | 4 |
| container_start_page | 369 |
| container_title | Clinical neuropharmacology |
| container_volume | 18 |
| creator | ROSSE, R. B KENDRICK, K TSUI, L. C FAY-MCCARTHY, M COLLINS, J. P ROSENBERG, P WYATT, R. J DEUTSCH, S. I |
| description | Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of approximately 10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo-controlled trials are needed to more fully evaluate the utility of famotidine in the treatment of schizophrenia. |
| doi_str_mv | 10.1097/00002826-199508000-00009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77841229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>77841229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-97591b0cd588fa8823f665b8d716504498d5d88e9d2eb80a63d2b091a3f319e93</originalsourceid><addsrcrecordid>eNo9UEtLAzEQDqLUWv0JQg7ibTWPTXbiTYpVoeBFwdsym2Tplu7DZCvUX--urZ3LMN9jZvgIoZzdcWayezaUAKETboxiMEzJCJkTMuVKZgnX4vOUTJnUIlFap-fkIsb1oACTmgmZgNZKKTYliwXWbV-5qvEU3Xrb2L769rRbYajRtv3KB-x2tC1ptKvqp-1WwTcV0geK1GL0NPiuDf0lOStxE_3Voc_Ix-Lpff6SLN-eX-ePy8QKSPvEZMrwglmnAEoEELIcHinAZVwrlqYGnHIA3jjhC2CopRMFMxxlKbnxRs7I7X5vF9qvrY99XlfR-s0GG99uY55lkHIhRiHshTa0MQZf5l2oagy7nLN8jDD_jzA_RvgHjdbrw41tUXt3NB4yG_ibA4_R4qYM2NgqHmVSp8A1k7_Ur3hA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77841229</pqid></control><display><type>article</type><title>Famotidine adjunctive pharmacotherapy of schizophrenia : a case report</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>ROSSE, R. B ; KENDRICK, K ; TSUI, L. C ; FAY-MCCARTHY, M ; COLLINS, J. P ; ROSENBERG, P ; WYATT, R. J ; DEUTSCH, S. I</creator><creatorcontrib>ROSSE, R. B ; KENDRICK, K ; TSUI, L. C ; FAY-MCCARTHY, M ; COLLINS, J. P ; ROSENBERG, P ; WYATT, R. J ; DEUTSCH, S. I</creatorcontrib><description>Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of approximately 10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo-controlled trials are needed to more fully evaluate the utility of famotidine in the treatment of schizophrenia.</description><identifier>ISSN: 0362-5664</identifier><identifier>EISSN: 1537-162X</identifier><identifier>DOI: 10.1097/00002826-199508000-00009</identifier><identifier>PMID: 8665550</identifier><identifier>CODEN: CLNEDB</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Biological and medical sciences ; Famotidine - therapeutic use ; Humans ; Male ; Medical sciences ; Middle Aged ; Molindone - therapeutic use ; Neuropharmacology ; Pharmacology. Drug treatments ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Schizophrenia - drug therapy</subject><ispartof>Clinical neuropharmacology, 1995-08, Vol.18 (4), p.369-374</ispartof><rights>1995 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3648160$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8665550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ROSSE, R. B</creatorcontrib><creatorcontrib>KENDRICK, K</creatorcontrib><creatorcontrib>TSUI, L. C</creatorcontrib><creatorcontrib>FAY-MCCARTHY, M</creatorcontrib><creatorcontrib>COLLINS, J. P</creatorcontrib><creatorcontrib>ROSENBERG, P</creatorcontrib><creatorcontrib>WYATT, R. J</creatorcontrib><creatorcontrib>DEUTSCH, S. I</creatorcontrib><title>Famotidine adjunctive pharmacotherapy of schizophrenia : a case report</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of approximately 10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo-controlled trials are needed to more fully evaluate the utility of famotidine in the treatment of schizophrenia.</description><subject>Biological and medical sciences</subject><subject>Famotidine - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molindone - therapeutic use</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Schizophrenia - drug therapy</subject><issn>0362-5664</issn><issn>1537-162X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UEtLAzEQDqLUWv0JQg7ibTWPTXbiTYpVoeBFwdsym2Tplu7DZCvUX--urZ3LMN9jZvgIoZzdcWayezaUAKETboxiMEzJCJkTMuVKZgnX4vOUTJnUIlFap-fkIsb1oACTmgmZgNZKKTYliwXWbV-5qvEU3Xrb2L769rRbYajRtv3KB-x2tC1ptKvqp-1WwTcV0geK1GL0NPiuDf0lOStxE_3Voc_Ix-Lpff6SLN-eX-ePy8QKSPvEZMrwglmnAEoEELIcHinAZVwrlqYGnHIA3jjhC2CopRMFMxxlKbnxRs7I7X5vF9qvrY99XlfR-s0GG99uY55lkHIhRiHshTa0MQZf5l2oagy7nLN8jDD_jzA_RvgHjdbrw41tUXt3NB4yG_ibA4_R4qYM2NgqHmVSp8A1k7_Ur3hA</recordid><startdate>19950801</startdate><enddate>19950801</enddate><creator>ROSSE, R. B</creator><creator>KENDRICK, K</creator><creator>TSUI, L. C</creator><creator>FAY-MCCARTHY, M</creator><creator>COLLINS, J. P</creator><creator>ROSENBERG, P</creator><creator>WYATT, R. J</creator><creator>DEUTSCH, S. I</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19950801</creationdate><title>Famotidine adjunctive pharmacotherapy of schizophrenia : a case report</title><author>ROSSE, R. B ; KENDRICK, K ; TSUI, L. C ; FAY-MCCARTHY, M ; COLLINS, J. P ; ROSENBERG, P ; WYATT, R. J ; DEUTSCH, S. I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-97591b0cd588fa8823f665b8d716504498d5d88e9d2eb80a63d2b091a3f319e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>Biological and medical sciences</topic><topic>Famotidine - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molindone - therapeutic use</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Schizophrenia - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ROSSE, R. B</creatorcontrib><creatorcontrib>KENDRICK, K</creatorcontrib><creatorcontrib>TSUI, L. C</creatorcontrib><creatorcontrib>FAY-MCCARTHY, M</creatorcontrib><creatorcontrib>COLLINS, J. P</creatorcontrib><creatorcontrib>ROSENBERG, P</creatorcontrib><creatorcontrib>WYATT, R. J</creatorcontrib><creatorcontrib>DEUTSCH, S. I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ROSSE, R. B</au><au>KENDRICK, K</au><au>TSUI, L. C</au><au>FAY-MCCARTHY, M</au><au>COLLINS, J. P</au><au>ROSENBERG, P</au><au>WYATT, R. J</au><au>DEUTSCH, S. I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Famotidine adjunctive pharmacotherapy of schizophrenia : a case report</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>1995-08-01</date><risdate>1995</risdate><volume>18</volume><issue>4</issue><spage>369</spage><epage>374</epage><pages>369-374</pages><issn>0362-5664</issn><eissn>1537-162X</eissn><coden>CLNEDB</coden><abstract>Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of approximately 10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone. The case suggests that some adjuvant efficacy exists for famotidine in at least some patients with schizophrenia. Placebo-controlled trials are needed to more fully evaluate the utility of famotidine in the treatment of schizophrenia.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>8665550</pmid><doi>10.1097/00002826-199508000-00009</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0362-5664 |
| ispartof | Clinical neuropharmacology, 1995-08, Vol.18 (4), p.369-374 |
| issn | 0362-5664 1537-162X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77841229 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Biological and medical sciences Famotidine - therapeutic use Humans Male Medical sciences Middle Aged Molindone - therapeutic use Neuropharmacology Pharmacology. Drug treatments Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Schizophrenia - drug therapy |
| title | Famotidine adjunctive pharmacotherapy of schizophrenia : a case report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A21%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Famotidine%20adjunctive%20pharmacotherapy%20of%20schizophrenia%20:%20a%20case%20report&rft.jtitle=Clinical%20neuropharmacology&rft.au=ROSSE,%20R.%20B&rft.date=1995-08-01&rft.volume=18&rft.issue=4&rft.spage=369&rft.epage=374&rft.pages=369-374&rft.issn=0362-5664&rft.eissn=1537-162X&rft.coden=CLNEDB&rft_id=info:doi/10.1097/00002826-199508000-00009&rft_dat=%3Cproquest_cross%3E77841229%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77841229&rft_id=info:pmid/8665550&rfr_iscdi=true |